AI compute accelerates; cure pipeline extends to children
LISTEN
Direct audio file (MP3)Global active cure-related trials now total 21,141, while the wire added 96 new signals in the last 24h and 42 new cure research updates—progress continues on both the clinical and intelligence tracks. On the capital/AI side, investment in data centers is accelerating despite component shortages and project frictions, and the paradox is sharpening: employees report individual AI productivity gains, yet McKinsey finds only 37% see positive EBIT impact, implying the translation from intelligence to enterprise economics still leaks. In parallel, biomedical execution delivered concrete reach: Janssen’s FDA label expansion extends Stelara for pediatric ulcerative colitis down to age two, and FDA approvals also advanced treatments across dermatomyositis (oral JAK inhibitor) and essential thrombocythemia. The throughline is restrained hope: the machine phase transition is colliding with the old scaling system, but medicine is still moving into younger patients and broader indications. The window is still open.
India’s data-centre boom is colliding with water-and-power stress as electricity, water, and heat loads strain grids.
Faster compute and better agentic platforms can accelerate discovery and development, but infrastructure stress and translation failures risk slowing the payoff for humanity.
Watch whether the AI-to-EBIT gap closes while pediatric and new FDA approvals keep expanding; the next 24–72 hours matter as the pipeline momentum compounds.